Literature DB >> 12433327

Pathogenesis of Recurrent Vulvovaginal Candidiasis.

Jack D. Sobel1.   

Abstract

Recurrent vulvovaginal candidiasis (RVVC) is by no means uncommon and is a source of considerable physical suffering, in addition to serving as a major therapeutic challenge. The syndrome is multifactorial in etiology, hence management strategies must recognize the complex etiologic pathways. Considerable progress has been made in identifying secondary causes, including biologic and host factors. Specifically, Candida microbiologic studies have revealed that azole resistance in Candida albicans is rare and infection by less sensitive non-albicans Candida species is uncommon. At least half the women with RVVC have no identifiable host or microbial predisposing factors, and an immune-based hypothesis has been generated.

Entities:  

Year:  2002        PMID: 12433327     DOI: 10.1007/s11908-002-0038-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  23 in total

1.  Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey.

Authors:  B Foxman; J V Marsh; B Gillespie; J D Sobel
Journal:  J Womens Health       Date:  1998-11       Impact factor: 2.681

2.  Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype.

Authors:  W Chaim; B Foxman; J D Sobel
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

3.  The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.

Authors:  J D Sobel; S E Ohmit; P Schuman; R S Klein; K Mayer; A Duerr; J A Vazquez; A Rampalo
Journal:  J Infect Dis       Date:  2001-01-15       Impact factor: 5.226

4.  Sexual behaviors and other risk factors for Candida vulvovaginitis.

Authors:  B D Reed; D W Gorenflo; B W Gillespie; C L Pierson; P Zazove
Journal:  J Womens Health Gend Based Med       Date:  2000 Jul-Aug

5.  Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy.

Authors:  D Rigg; M M Miller; W J Metzger
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

Review 6.  Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations.

Authors:  J D Sobel; S Faro; R W Force; B Foxman; W J Ledger; P R Nyirjesy; B D Reed; P R Summers
Journal:  Am J Obstet Gynecol       Date:  1998-02       Impact factor: 8.661

7.  Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis.

Authors:  E Hilton; H D Isenberg; P Alperstein; K France; M T Borenstein
Journal:  Ann Intern Med       Date:  1992-03-01       Impact factor: 25.391

8.  Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.

Authors:  Suzanne E Ohmit; Jack D Sobel; Paula Schuman; Ann Duerr; Kenneth Mayer; Anne Rompalo; Robert S Klein
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

9.  Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.

Authors:  M E Lynch; J D Sobel
Journal:  J Med Vet Mycol       Date:  1994

10.  Strain-dependent differences in host response to Candida albicans infection in mice are related to organ susceptibility and infectious load.

Authors:  R B Ashman; A Fulurija; J M Papadimitriou
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more
  12 in total

1.  Vulvovaginal candidiasis.

Authors:  Jeanne Marrazzo
Journal:  BMJ       Date:  2003-05-10

2.  Management of recurrent vulvovaginal candidiasis: unresolved issues.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

3.  A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections.

Authors:  Brice Enjalbert; Anna Rachini; Govindsamy Vediyappan; Donatella Pietrella; Roberta Spaccapelo; Anna Vecchiarelli; Alistair J P Brown; Christophe d'Enfert
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

4.  Sensitivity of Candida albicans germ tubes and biofilms to photofrin-mediated phototoxicity.

Authors:  Yeissa Chabrier-Roselló; Thomas H Foster; Nelissa Pérez-Nazario; Soumya Mitra; Constantine G Haidaris
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Annexin-A1 identified as the oral epithelial cell anti-Candida effector moiety.

Authors:  E A Lilly; J Yano; P L Fidel
Journal:  Mol Oral Microbiol       Date:  2010-08       Impact factor: 3.563

6.  Oral and vaginal epithelial cell anti-Candida activity is acid labile and does not require live epithelial cells.

Authors:  J Yano; E A Lilly; C Steele; D Fortenberry; P L Fidel
Journal:  Oral Microbiol Immunol       Date:  2005-08

7.  Associations between bacterial vaginosis, candida vaginitis, trichomonas vaginalis, and vaginal pathogenic community in Chinese women.

Authors:  Dandan Yuan; Wen Chen; Junjie Qin; Dongqian Shen; Youlin Qiao; Beihua Kong
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis.

Authors:  Zongxin Ling; Jianming Kong; Fang Liu; Haibin Zhu; Xiaoyi Chen; Yuezhu Wang; Lanjuan Li; Karen E Nelson; Yaxian Xia; Charlie Xiang
Journal:  BMC Genomics       Date:  2010-09-07       Impact factor: 3.969

Review 9.  Management of patients with recurrent vulvovaginal candidiasis.

Authors:  Jack D Sobel
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR.

Authors:  Beatrice Vitali; Ciro Pugliese; Elena Biagi; Marco Candela; Silvia Turroni; Gert Bellen; Gilbert G G Donders; Patrizia Brigidi
Journal:  Appl Environ Microbiol       Date:  2007-07-20       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.